VR Adviser’s Viridian Therapeutics VRDN Stock Holding History

VR Adviser’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.8M	Sell	3,257,917 -624,792	-16%	-$10.1M	1.81%	11
2026 Q1	$75.9M	Hold	3,882,709	–	–	2.83%	10
2025 Q4	$121M	Hold	3,882,709	–	–	5.97%	3
2025 Q3	$83.8M	Hold	3,882,709	–	–	4.72%	5
2025 Q2	$54.3M	Hold	3,882,709	–	–	4.07%	7
2025 Q1	$52.3M	Hold	3,882,709	–	–	4.45%	6
2024 Q4	$74.4M	Hold	3,882,709	–	–	5.11%	5
2024 Q3	$88.3M	Buy	3,882,709 +38	+0%	+$621	4.63%	4
2024 Q2	$50.5M	Hold	3,882,671	–	–	3.22%	11
2024 Q1	$68M	Buy	3,882,671 +48	+0%	+$931	3.23%	9
2023 Q4	$84.6M	Buy	3,882,623 +800,001	+26%	+$12.6M	5.8%	4
2023 Q3	$47.3M	Hold	3,082,622	–	–	4.98%	3
2023 Q2	$73.3M	Buy	3,082,622 +382,757	+14%	+$9.82M	11.73%	1
2023 Q1	$68.7M	Hold	2,699,865	–	–	13.41%	1
2022 Q4	$78.9M	Buy	2,699,865 +569,557	+27%	+$13.1M	13.29%	1
2022 Q3	$43.7M	Buy	2,130,308 +277,389	+15%	+$4.99M	6.74%	5
2022 Q2	$21.4M	Hold	1,852,919	–	–	4.22%	9
2022 Q1	$34.3M	Hold	1,852,919	–	–	5.55%	7
2021 Q4	$36.6M	Buy	1,852,919 +1,833,424	+9,405%	+$34.2M	5.01%	7
2021 Q3	$321K	Hold	19,495	–	–	0.04%	26
2021 Q2	$357K	Hold	19,495	–	–	0.04%	29
2021 Q1	$326K	Hold	19,495	–	–	0.04%	28
2020 Q4	$321K	Buy	+19,495	New	+$294K	0.05%	25

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

VR Adviser's VRDN Position: Q2 2026 in Review

VR Adviser reduced its Viridian Therapeutics (VRDN) stake by 16% in Q2 2026, selling an estimated $10.1M and leaving 3,257,917 shares worth $59.8M. The position accounts for 1.81% of the portfolio, ranked #11.

VR Adviser first reported a position in VRDN in Q4 2020 and has held it in 23 quarters since. The position peaked at $121M in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

VR Adviser held 3,257,917 shares of Viridian Therapeutics worth $59.8M as of Q2 2026.
VR Adviser sold 624,792 Viridian Therapeutics shares in Q2 2026, an estimated $10.1M.
Viridian Therapeutics made up 1.81% of VR Adviser's portfolio in Q2 2026, its #11 holding.
VR Adviser first reported a position in Viridian Therapeutics in Q4 2020 and has held it in 23 quarters since.
VR Adviser's Viridian Therapeutics position peaked at $121M in Q4 2025.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.